Cemiplimab may reduce the need for exenteration in patients with orbital tumors
- Posted on: Aug 22 2023
- Leave a response
The programmed cell death-1 inhibitor cemiplimab was studied under real-world conditions for its efficacy in treating squamous cell carcinoma with orbital invasion.
Source: AAO
Posted in: Uncategorized
